etidronate has been researched along with Osteosclerosis in 4 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Osteosclerosis: An abnormal hardening or increased density of bone tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis." | 5.29 | Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. ( Camaschella, C; Cesano, L; Guerrasio, A; Mazza, U; Sivera, P, 1994) |
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "Haematologic malignancies and solid tumors are often complicated by the bone tissue destruction." | 2.39 | [Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. ( Kiełbiński, M, 1994) |
| "Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis." | 1.29 | Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis. ( Camaschella, C; Cesano, L; Guerrasio, A; Mazza, U; Sivera, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamada, H | 1 |
| Matsuo, A | 1 |
| Koizumi, T | 1 |
| Satomi, T | 1 |
| Chikazu, D | 1 |
| Oizumi, T | 1 |
| Funayama, H | 1 |
| Yamaguchi, K | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Kawamura, H | 1 |
| Sugawara, S | 1 |
| Endo, Y | 1 |
| Kiełbiński, M | 1 |
| Sivera, P | 1 |
| Cesano, L | 1 |
| Guerrasio, A | 1 |
| Camaschella, C | 1 |
| Mazza, U | 1 |
1 review available for etidronate and Osteosclerosis
| Article | Year |
|---|---|
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis].
Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteo | 1994 |
3 other studies available for etidronate and Osteosclerosis
| Article | Year |
|---|---|
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Ass | 2014 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis.
Topics: Aged; Etidronic Acid; Follow-Up Studies; Humans; Male; Osteosclerosis; Primary Myelofibrosis | 1994 |